Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
80
NCT02914353
Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 31, 2016
Completion: May 31, 2017
NCT05040776
COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients
Phase: Phase 2
Start: Oct 31, 2023
Completion: May 31, 2025